Combining Traditional Chinese Medicine with Ranibizumab for Macular Edema Treatment
Traditional Chinese Medicine and Ranibizumab in the Treatment of Macular Cystoid Edema Associated with Retinal Vein Obstruction.
This study is testing if combining a traditional Chinese medicine with a common eye injection can help people with macular edema see better and need fewer treatments.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dongyang People's Hospital Government |
| Drugs / interventions | ranibizumab |
| Locations | 1 site (Dongyang, Zhejiang) |
| Trial ID | NCT06234514 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and safety of a traditional Chinese medicine called Jueling Mingmu Decoction in conjunction with ranibizumab for treating macular cystoid edema caused by retinal vein obstruction. The goal is to determine if this combined approach is more effective than using ranibizumab alone, potentially leading to better visual outcomes and fewer required injections. Participants will receive both the decoction and intravitreal injections of ranibizumab to assess improvements in their condition.
Who should consider this trial
Good fit: Ideal candidates are individuals with foveal center-involved macular edema lasting less than 9 months and specific visual acuity levels.
Not a fit: Patients with additional macular pathologies or serious concurrent health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance treatment outcomes for patients suffering from macular cystoid edema.
How similar studies have performed: While the combination of traditional Chinese medicine with modern treatments is less common, similar integrative approaches have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Foveal center-involved macular edema (ME) lasting less than 9 months * Central Macular Thickness (CMT) greater than or equal to 250 μm * Best-Corrected Visual Acuity (BCVA) of 24-73 letters (20/40 to 20/320) in the study eye * Initial diagnosis with no prior treatments, such as laser therapy or intravitreal injections Exclusion Criteria: * Presence of any additional macular pathology, such as age-related macular degeneration (AMD) or diabetic retinopathy (DR) affecting the macula * Concurrent serious conditions, such as cardiovascular diseases, liver, or kidney diseases * Concerns or doubts regarding treatment * Known allergies to the ingredients of the medication.
Where this trial is running
Dongyang, Zhejiang
- Dongyang People's Hospital — Dongyang, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Hongyan Wu
- Email: hongyanwu1982@163.com
- Phone: +13967490168
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.